-
Mashup Score: 0Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients - 9 day(s) ago
MicroabstractWe analyzed vaccination rates and associated outcomes of patients with multiple myelom in the INSIGHT MM study. Influenza vaccination in the prior 2 years and pneumococcal vaccination in the prior 5 years impacted overall survival versus no vaccination. Additionally, deaths due to infections were lower among vaccinated versus non-vaccinated patients. Vaccination status should be recorded in prospective clinical trials as it may affect survival.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Treatment of chronic COVID‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies - 9 day(s) ago
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
Treatment of chronic COVID-19 with convalescent / postvaccination plasma in patients with hematologic malignancies [May 9, 2024] Janssen et al. @IntJCanc https://t.co/HtpbyAHNKB #COVID19CP #COVID19nCancer #COVID19 https://t.co/0vO023A8iD
-
-
Mashup Score: 2Mobile - 9 day(s) ago
High Titer COVID-19 Convalescent Plasma is now available to order through OneBlood.
Source: www.oneblood.orgCategories: General Medicine News, Hem/OncsTweet-
Licensed High Titer COVID-19 Convalescent Plasma (CCP): ORDER FORM. OneBlood Receives @US_FDA Approval https://t.co/8rjvWTvDWW #COVID19CP #COVID19 Press Release (1/13/25): https://t.co/LKxgzaioxg HT @ACasadevall1 cc @DrMJoyner @DrJPHenderson
-
-
Mashup Score: 1Survival in Patients With Hematologic Cancers and COVID-19 - 9 day(s) ago
This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
Convalescent Plasma and Survival in Hematologic Malignancy and COVID-19 [Jun 17, 2021] @mtmdphd & @DrJPHenderson et al. @jwsenefeld @DrDimpyShah @hemoncwarner @COVID19nCCC - @JAMAOnc https://t.co/g3GP7EsUeS #COVID19CP #CCC19 #COVID19nCancer #COVID19 #IDonc
-
-
Mashup Score: 0Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19 - 9 day(s) ago
Patients treated recently for a B-lymphoid malignancy are shown to have particularly high risks of severe COVID-19 compared to multiple control cohorts of patients with cancer and COVID-19.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a #CCC19 registry analysis [Mar 9, 2022] @rubinstein_md et al. @mtmdphd @COVID19nCCC @BCD_AACR https://t.co/IMEbvgZafi #COVID19nCancer #COVID19 #bmtsm #leusm #lymsm #mmsm #mpnsm https://t.co/Vt5TF5hVZG
-
-
Mashup Score: 1
Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID-19 and Cancer Consortium (CCC19) to identify prognostic clinical factors, including laboratory measurements and anticancer therapies.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet-
Association of Clinical Factors & Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium [3/18/21] @PGrivasMDPhD @arkhaki et al. @COVID19nCCC @Annals_Oncology https://t.co/WH5PPJySj6 #CCC19 #COVID19nCancer https://t.co/5tkdMEWUXx
-
-
Mashup Score: 3PP01.52 The Effect of Altered RNA Expression on Tumor Immune Infiltration in NSCLC: A Retrospective NGS Study - 19 day(s) ago
Molecular testing has identified an increasing number of NSCLC associated genes, but their exact roles are poorly understood. The development of immune checkpoint inhibitors (ICIs) has improved NSCLC outcomes, but there are still limited predictive biomarkers for ICI response. We hypothesize that altered RNA expression impacts tumor immune infiltration in NSCLC and that these relationships can help guide biomarker development.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
PP01.52 The Effect of Altered RNA Expression on Tumor Immune Infiltration in NSCLC: A Retrospective NGS Study [Jul 2024] Faith et al. @RyanNguyenDO @IASLC J Thoracic Oncol https://t.co/REQvz25eS3 #PrecisionMedicine #ImmunoOnc #lcsm
-
-
Mashup Score: 0Frequency of Common and Uncommon BRAF Alterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies - 19 day(s) ago
Background: The predictive and prognostic role of BRAF alterations has been evaluated in colorectal cancer (CRC); however, BRAF alterations have not been fully characterized in non-CRC gastrointestinal (GI) malignancies. In the present study, we report the frequency and spectrum of BRAF alterations among patients with non-CRC GI malignancies. Methods: Patients with CRC and non-CRC GI malignancies who underwent somatic tumor profiling via a tissue-based or liquid-based assay were included in this study. Gain-of-function BRAF alterations were defined as pathogenic/likely pathogenic somatic short variants (SVs), copy number amplifications ≥8, or fusions (RNA or DNA). Results: Among 51,560 patients with somatic profiling, 40% had CRC and 60% had non-CRC GI malignancies. BRAF GOF alterations were seen more frequently in CRC (8.9%) compared to non-CRC GI malignancies (2.2%) (p < 0.001). Non-CRC GI malignancies with the highest prevalence of BRAF GOF alterations were bile duct cancers (4.1%)
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet-
Frequency of Common and Uncommon BRAFAlterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies [May 10, 2024] @Amitmahipal79 et al. Cancers https://t.co/xONNaih4nc #PrecisionMedicine #crcsm #esocsm #hpbcsm #pancsm #sbcsm #stcsm https://t.co/yLlU6NFS1J
-
-
Mashup Score: 1
Background: The frequency of HER2 expression in solid tumors other than breast (BC) and gastric cancer (GC) is not well defined. This study describes the frequency of HER2 expression by correlating HER2 IHC/ ISH and ERBB2 mRNA levels by NGS in tumor samples of patients with locally advanced/metastatic (LA/m) BC or GC and applying those findings … Continued
Source: www.tempus.comCategories: General Medicine News, Hem/OncsTweet-
Analysis of HER2 Prevalence by RNA Expression Across Solid Tumors [Mar 22, 2024] Moxley et al. @CharuAggarwalMD #AACR24 Abstract 5148 @CR_AACR @TempusAI https://t.co/ayCIqw4t2z #PrecisionMedicine https://t.co/FpTj12RNoI
-
-
Mashup Score: 1Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy - 19 day(s) ago
This cohort study evaluates tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
Assessment of Tumor Mutational Burden [#TMB] and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy [May 2, 2023] @CharuAggarwalMD et al. @JPatelMD @JAMANetworkOpen https://t.co/26qHIi8CzA #ImmunoOnc #PrecisionMedicine #lcsm @TempusLabs https://t.co/lN60HDJLx7
-
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML https://t.co/kUQeRmdKWV #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx https://t.co/IBFVjp7ytJ